September 4, 2024 by Jason Wertheimer Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron under Ongoing Collaboration Read More
November 6, 2023 by Jason Wertheimer Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2023 Read More
October 13, 2023 by Jason Wertheimer Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy at Symposium on Hidradenitis Suppurativa Advances Read More
September 29, 2023 by Jason Wertheimer Sonoma Bio Sonoma Biotherapeutics Appoints Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, as Chief Medical Officer Read More
May 4, 2023 by Jason Wertheimer Sonoma Bio Co-Founder and Chief Executive Officer Jeffrey Bluestone, Ph.D., Elected to the National Academy of Sciences Read More
April 11, 2023 by Jason Wertheimer Sonoma Biotherapeutics Appoints Leaders in Cell Therapy and Immunology to Scientific Advisory Board Read More
March 28, 2023 by Jason Wertheimer Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases Read More
November 10, 2022 by Jason Wertheimer Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2022 Read More
September 7, 2022 by Jason Wertheimer Sonoma Biotherapeutics Appoints Jessica Stitt as Chief Financial Officer Read More
August 24, 2022 by Jason Wertheimer Sonoma Biotherapeutics Enters Long-Term Lease Agreement to Establish a Treg Cell Therapy R&D and Manufacturing Center Read More